Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation [PDF]
, 2020 INTRODUCTION Cytomegalovirus (CMV) infection following allogeneic hematopoietic stem cell transplantation (HSCT) is a major cause of morbidity and mortality.
Mehra, V +3 more
core
A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection
Expert Review of Vaccines, 2018 Introduction: It has been almost fifty years since the Towne strain was used by Plotkin and collaborators as the first vaccine candidate for cytomegalovirus (CMV).
Don Jeffrey Diamond +8 more
doaj +1 more source
PP105 Efficacy, Effectiveness And Safety Of Letermovir For Prophylaxis Of Cytomegalovirus Infection And Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation [PDF]
, 2023 Roberto Lúcio Muniz Júnior +9 more
openalex +1 more source
2740. Letermovir for the Prevention and Treatment of Cytomegalovirus Infection in Solid Organ Transplant Recipients [PDF]
, 2023 Xhilda Xhemali +2 more
openalex +1 more source
Antiviral resistance and persistent replication of cytomegalovirus and SARS-CoV-2 in immunocompromised patients [PDF]
, 2022 [eng] The main objectives of this thesis are to study the opportunistic infection caused by human cytomegalovirus and SARS-CoV-2 inquiring persistent infection and antiviral resistance.
Santos Bravo, Marta
core +1 more source
Human neural progenitor cell models to study the antiviral effects and neuroprotective potential of approved and investigational human cytomegalovirus inhibitors [PDF]
Human cytomegalovirus (HCMV) is the viral leading cause of congenital defects in newborns worldwide. Many aspects of congenital CMV (cCMV) infection, which currently lacks a specific treatment, as well as the main determinants of neuropathogenesis in the
Apolloni L. +8 more
core +4 more sources
Mediterranean Journal of Hematology and Infectious Diseases, 2019 CMV associated tissue-invasive disease is associated with a considerable risk of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Recently, the terminase inhibitor letermovir (LMV) has been approved for prophylaxis
Jochen J Frietsch +8 more
doaj +1 more source
Letermovir Analytical Methods Development and Validation: In-Silico Insights and Characterization [PDF]
Combining computational and experimental methods is necessary due to the increasing complexity of antiviral drug discovery and the requirement for robust analytical quality control.
Ritika Pal, Vaishali, Sudhansu Ranjan Swain
core +1 more source
Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: clinical and in vitro examination of endothelial activation [PDF]
Since 2021 the use of G-CSF was implemented in allo-HCT with PTCY-based prophylaxis with the aim of shortening the aplastic phase and reducing infectious complications. This study investigates the effectiveness of this change in protocol performed at our
Carcelero San Martin, Esther +23 more
core +1 more source